Procaps Group SA
PROC
Company Profile
Business description
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Contact
9 Rue de Bitbourg
LuxembourgL-1273
LUXT: +356 79956138
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
5,500
Stocks News & Analysis
stocks
Trouble continues as Star Entertainment burns through cash
More pain in the horizon as the company struggles to stay afloat.
stocks
Vote in favour of merger for undervalued ASX share
We recommend shareholders vote in favor of its proposed merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,557.40 | 11.70 | -0.14% |
| CAC 40 | 7,709.75 | 75.01 | 0.98% |
| DAX 40 | 20,903.39 | 248.00 | 1.20% |
| Dow JONES (US) | 43,487.83 | 334.70 | 0.78% |
| FTSE 100 | 8,505.22 | 113.32 | 1.35% |
| HKSE | 19,584.06 | 61.17 | 0.31% |
| NASDAQ | 19,630.20 | 291.91 | 1.51% |
| Nikkei 225 | 38,451.46 | 121.14 | -0.31% |
| NZX 50 Index | 13,130.43 | 129.76 | 1.00% |
| S&P 500 | 5,996.66 | 59.32 | 1.00% |
| S&P/ASX 200 | 8,310.40 | 16.60 | -0.20% |
| SSE Composite Index | 3,241.82 | 5.79 | 0.18% |